• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Large owner Ai Day1 Llc

    4/27/26 5:27:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DAWN alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    AI Day1 LLC

    (Last)(First)(Middle)
    C/O ACCESS INDUSTRIES, INC.
    40 WEST 57TH STREET, 28TH FLOOR

    (Street)
    NEW YORK NEW YORK 10019

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Day One Biopharmaceuticals, Inc. [ DAWN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/23/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    XForm filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock04/23/2026U(1)12,929,322(1)D$21.50D(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Pre-Funded Warrant (right to buy)$0.000104/23/2026D(1)827,586(1) (3) (3)Common Stock827,586$21.49990D(2)
    1. Name and Address of Reporting Person*
    AI Day1 LLC

    (Last)(First)(Middle)
    C/O ACCESS INDUSTRIES, INC.
    40 WEST 57TH STREET, 28TH FLOOR

    (Street)
    NEW YORK NEW YORK 10019

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Access Industries Holdings LLC

    (Last)(First)(Middle)
    C/O ACCESS INDUSTRIES, INC.
    40 WEST 57TH STREET, 28TH FLOOR

    (Street)
    NEW YORK NEW YORK 10019

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    ACCESS INDUSTRIES MANAGEMENT, LLC

    (Last)(First)(Middle)
    C/O ACCESS INDUSTRIES, INC.
    40 WEST 57TH STREET, 28TH FLOOR

    (Street)
    NEW YORK NEW YORK 10019

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    1. Name and Address of Reporting Person*
    Blavatnik Len

    (Last)(First)(Middle)
    C/O ACCESS INDUSTRIES, INC.
    40 WEST 57TH STREET, 28TH FLOOR

    (Street)
    NEW YORK NEW YORK 10019

    (City)(State)(Zip)

    UNITED STATES

    (Country)

    Relationship of Reporting Person(s) to Issuer
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    Explanation of Responses:
    1. On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. ("Purchaser") to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026. Such shares were accepted by the Purchaser on April 23, 2026. On April 23, 2026, in connection with the consummation of the merger, each pre-funded warrant held by AI Day1 to purchase Common Stock was converted into the right to receive $21.4999 per warrant in cash.
    2. The securities reported are held directly by AI Day1 LLC ("AI Day1") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Day1. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
    3. Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Day1 LLC, including together with its direct or indirect affiliates, any person acting or who could be deemed to be acting as a group together with the holder, and any other persons whose beneficial ownership of the Common Stock would or could be aggregated with the holder's for the purposes of Section 13(d) or Section 16 of the Exchange Act of 1934, as amended, immediately following such exercise would exceed 9.99%; provided, however, that AI Day1 LLC may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.
    /s/ Alejandro Moreno for AI Day1 LLC04/27/2026
    /s/ Alejandro Moreno for Access Industries Holdings LLC04/27/2026
    /s/ Alejandro Moreno for Access Industries Management, LLC04/27/2026
    /s/ Alejandro Moreno, as Attorney-in-Fact for Mr. Blavatnik04/27/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $DAWN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DAWN

    DatePrice TargetRatingAnalyst
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    1/13/2026$34.00Buy
    TD Cowen
    8/19/2025$25.00Overweight
    Piper Sandler
    10/9/2024$32.00 → $33.00Buy
    Needham
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    4/24/2024$30.00 → $33.00Buy
    Needham
    4/25/2023$34.00 → $9.00Buy → Underperform
    BofA Securities
    2/8/2023$40.00Overweight
    CapitalOne
    More analyst ratings

    $DAWN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Day One Biopharmaceuticals Inc.

    SCHEDULE 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    5/14/26 4:19:51 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Day One Biopharmaceuticals Inc.

    15-12G - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

    5/4/26 6:02:01 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Day One Biopharmaceuticals Inc.

    25-NSE - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    4/23/26 9:14:52 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Ai Day1 Llc

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/27/26 5:27:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:40:56 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    4/23/26 4:39:50 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    10/20/23 4:02:31 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Day One Biopharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Day One Biopharmaceuticals from Buy to Neutral and set a new price target of $21.50

    3/10/26 8:39:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Day One Biopharmaceuticals with a new price target

    Piper Sandler initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $25.00

    8/19/25 8:33:40 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Servier completes the acquisition of Day One Biopharmaceuticals

    Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade glioma. Transaction also includes a strong oncology pipeline of clinical stage assets in rare cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion.SURESNES, France, April 23, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and com

    4/23/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care

    Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ

    3/19/26 10:00:00 AM ET
    $DAWN
    $ENGN
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

    Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion.SURESNES, France and BRISBANE, Calif., March 6, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One f

    3/6/26 10:21:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Leadership Updates

    Live Leadership Updates

    View All

    Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

    Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an

    6/10/25 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

    Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

    11/20/24 4:30:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Announces Two New Appointments to Board of Directors

    BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou

    1/17/24 8:00:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Financials

    Live finance-specific insights

    View All

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

    BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025. Live audio of the webcast will be accessible by visiting the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days follo

    2/10/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

    Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need and a lack of therapeutic options Day One will apply existing scientific and commercial capabilities to this investigational innovative therapeutic with a clear potential registration path Company to host conference call and webcast today, November 13, 8:00 am Eastern Time BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company

    11/13/25 6:00:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/14/24 4:30:11 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/7/24 9:24:55 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

    SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/7/24 9:12:22 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care